Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction

• DOI: 10.1007/s00395-016-0530-0
• Publication Date: 2016-01-23T08:26:52Z
• Authors: Daniela Malan; Miao Zhang; Birgit Stallmeyer; Jovanca Müller; Bernd K. Fleischmann; Eric Schulze-Bahr; Philipp Sasse; Boris Greber
• Keywords: 0301 basic medicine; 0303 health sciences; Patch-Clamp Techniques; Physiology; Induced Pluripotent Stem Cells; Original Contribution; NAV1.5 Voltage-Gated Sodium Channel; 3. Good health; Long QT Syndrome; 03 medical and health sciences; Phenotype; Cardiac Conduction System Disease; Physiology (medical); Humans; Myocytes, Cardiac; Cardiology and Cardiovascular Medicine; Cells, Cultured

Long QT syndrome is a potentially life-threatening disease characterized by delayed repolarization of cardiomyocytes, QT interval prolongation in the electrocardiogram, and a high risk for sudden cardiac death caused by ventricular arrhythmia. The genetic type 3 of this syndrome (LQT3) is caused by gain-of-function mutations in the SCN5A cardiac sodium channel gene which mediates the fast Nav1.5 current during action potential initiation. Here, we report the analysis of LQT3 human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). These were generated from a patient with a heterozygous p.R1644H mutation in SCN5A known to interfere with fast channel inactivation. LQT3 hiPSC-CMs recapitulated pathognomonic electrophysiological features of the disease, such as an accelerated recovery from inactivation of sodium currents as well as action potential prolongation, especially at low stimulation rates. In addition, unlike previously described LQT3 hiPSC models, we observed a high incidence of early after depolarizations (EADs) which is a trigger mechanism for arrhythmia in LQT3. Administration of specific sodium channel inhibitors was found to shorten action and field potential durations specifically in LQT3 hiPSC-CMs and antagonized EADs in a dose-dependent manner. These findings were in full agreement with the pharmacological response profile of the underlying patient and of other patients from the same family. Thus, our data demonstrate the utility of patient-specific LQT3 hiPSCs for assessing pharmacological responses to putative drugs and for improving treatment efficacies.